Selected polymorphic variants of the SDR5A1 and SRD5A2 genes can influence the activity of hormones that are essential for BPH etiology, thus contributing to individual responsiveness to treatment [11]. This evidence concerns the gene SRD5A2 and benign prostatic hyperplasia.